Cargando…

Co-expressing LRP6 With Anti-CD19 CAR-T Cells for Improved Therapeutic Effect Against B-ALL

BACKGROUND: Cellular immunotherapies, such as chimeric antigen receptor modified-T cell (CAR-T) therapy, offers excellent potential for tumor treatment. The memory phenotype of CAR-T has been correlated positively with a therapeutic effect on and prognosis of cancer. METHOD: The proliferation rates...

Descripción completa

Detalles Bibliográficos
Autores principales:	He, Ping, Tan, Zhongqiu, Wei, Zhongheng, Wan, Cheng-Liang, Yang, Shan-Shan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7522530/ https://www.ncbi.nlm.nih.gov/pubmed/33042788 http://dx.doi.org/10.3389/fonc.2020.01346

Ejemplares similares

Long-Term Safety and Efficacy of CD19 Humanized Selective CAR-T Therapy in B-ALL Patients Who Have Previously Received Murine-Based CD19 CAR-T Therapy
por: Zhao, Yu, et al.
Publicado: (2022)

Sclerostin Suppression Facilitates Uveal Melanoma Progression Through Activating Wnt/β-Catenin Signaling Via Binding to Membrane Receptors LRP5/LRP6
por: Wang, Hanqing, et al.
Publicado: (2022)

Case Report: Sirolimus Alleviates Persistent Cytopenia After CD19 CAR-T-Cell Therapy
por: Xing, Limin, et al.
Publicado: (2021)

Acute Graft-Versus-Host Disease After Humanized Anti-CD19-CAR T Therapy in Relapsed B-ALL Patients After Allogeneic Hematopoietic Stem Cell Transplant
por: Liu, Pengjiang, et al.
Publicado: (2020)

CD19 and CD30 CAR T-Cell Immunotherapy for High-Risk Classical Hodgkin’s Lymphoma
por: Xue, YuanBo, et al.
Publicado: (2021)

Oncolytic herpes simplex virus delivery of dual CAR targets of CD19 and BCMA as well as immunomodulators to enhance therapeutic efficacy in solid tumors combined with CAR T cell therapy
por: Liu, Yuanyuan, et al.
Publicado: (2022)

Failure of ALL recognition by CAR T cells: a review of CD 19-negative relapses after anti-CD 19 CAR-T treatment in B-ALL
por: Aparicio-Pérez, Clara, et al.
Publicado: (2023)

Successful Treatment of Refractory and Relapsed CNS Acute Lymphoblastic Leukemia With CD-19 CAR-T Immunotherapy: A Case Report
por: Htun, Kyaw Thu, et al.
Publicado: (2021)

Hypoxia-Induced miR-137 Inhibition Increased Glioblastoma Multiforme Growth and Chemoresistance Through LRP6
por: Li, Dong-Mei, et al.
Publicado: (2021)

Development of a Novel Anti-CD19 CAR Containing a Fully Human scFv and Three Costimulatory Domains
por: Wutti-in, Yupanun, et al.
Publicado: (2022)

CD44 regulates Wnt signaling at the level of LRP6
por: Orian-Rousseau, Véronique, et al.
Publicado: (2015)

Safety and efficacy of co-administration of CD19 and CD22 CAR-T cells in children with B-ALL relapse after CD19 CAR-T therapy
por: Li, Wenjie, et al.
Publicado: (2023)

LRP5 and LRP6 in Wnt Signaling: Similarity and Divergence
por: Ren, Qian, et al.
Publicado: (2021)

Oxidized phospholipids are ligands for LRP6
por: Wang, Lei, et al.
Publicado: (2018)

Outcomes of Anti-CD19 CAR-T Treatment of Pediatric B-ALL with Bone Marrow and Extramedullary Relapse
por: Wan, Xinyu, et al.
Publicado: (2022)

Intensive Debulking Chemotherapy Improves the Short-Term and Long-Term Efficacy of Anti-CD19-CAR-T in Refractory/Relapsed DLBCL With High Tumor Bulk
por: Lyu, Cuicui, et al.
Publicado: (2021)

CD22-CAR T Cells Induce Remissions in CD19-CAR Naïve and Resistant B-ALL
por: Fry, Terry J., et al.
Publicado: (2017)

Short-Interval Sequential CAR-T Cell Infusion May Enhance Prior CAR-T Cell Expansion to Augment Anti-Lymphoma Response in B-NHL
por: Meng, Yuan, et al.
Publicado: (2021)

Anti-LRP2 Nephropathy
por: Gallan, Alexander J., et al.
Publicado: (2020)

Corrigendum: Short-Interval Sequential CAR-T Cell Infusion May Enhance Prior CAR-T Cell Expansion to Augment Anti-Lymphoma Response in B-NHL
por: Meng, Yuan, et al.
Publicado: (2021)

Beyond CAR T Cells: Other Cell-Based Immunotherapeutic Strategies Against Cancer
por: Patel, Shabnum, et al.
Publicado: (2019)

Successful Anti-CLL1 CAR T-Cell Therapy in Secondary Acute Myeloid Leukemia
por: Zhang, Hui, et al.
Publicado: (2020)

Efficacy and safety of CD22-specific and CD19/CD22-bispecific CAR-T cell therapy in patients with hematologic malignancies: A systematic review and meta-analysis
por: Li, Lili, et al.
Publicado: (2022)

MIF promotes cell invasion by the LRP1-uPAR interaction in pancreatic cancer cells
por: Sun, Huizhi, et al.
Publicado: (2023)

Dissecting Molecular Differences between Wnt Coreceptors LRP5 and LRP6
por: MacDonald, Bryan T., et al.
Publicado: (2011)

Infectious Complications in Pediatric, Adolescent and Young Adult Patients Undergoing CD19-CAR T Cell Therapy
por: Maron, Gabriela M., et al.
Publicado: (2022)

PSMA-Specific CAR-Engineered T Cells for Prostate Cancer: CD28 Outperforms Combined CD28-4-1BB “Super-Stimulation”
por: Zuccolotto, Gaia, et al.
Publicado: (2021)

Dkk1 Stabilizes Wnt Co-Receptor LRP6: Implication for Wnt Ligand-Induced LRP6 Down-Regulation
por: Li, Yonghe, et al.
Publicado: (2010)

A novel full-human CD22-CAR T cell therapy with potent activity against CD22(low) B-ALL
por: Tan, Yue, et al.
Publicado: (2021)

PD-1(+) IFN-γ(+) subset of CD8(+) T cell in circulation predicts response to anti–PD-1 therapy in NSCLC
por: Chen, Wenxiu, et al.
Publicado: (2023)

Wnt co-receptors Lrp5 and Lrp6 differentially mediate Wnt3a signaling in osteoblasts
por: Sebastian, Aimy, et al.
Publicado: (2017)

Where Wnts Went: The Exploding Field of Lrp5 and Lrp6 Signaling in Bone
por: Williams, Bart O, et al.
Publicado: (2009)

Mechanisms underlying CD19-positive ALL relapse after anti-CD19 CAR T cell therapy and associated strategies
por: Nie, Yuru, et al.
Publicado: (2020)

A Novel CAR Expressing NK Cell Targeting CD25 With the Prospect of Overcoming Immune Escape Mechanism in Cancers
por: Dehbashi, Moein, et al.
Publicado: (2021)

Clinical Outcomes of BCMA CAR-T Cells in a Multiple Myeloma Patient With Central Nervous System Invasion
por: Wang, Ting, et al.
Publicado: (2022)

From CAR-T Cells to CAR-NK Cells: A Developing Immunotherapy Method for Hematological Malignancies
por: Lu, Hui, et al.
Publicado: (2021)

In-Vivo Induced CAR-T Cell for the Potential Breakthrough to Overcome the Barriers of Current CAR-T Cell Therapy
por: Xin, Tianqing, et al.
Publicado: (2022)

Positive Allosteric Modulation of CD11b as a Novel Therapeutic Strategy Against Lung Cancer
por: Geraghty, Terese, et al.
Publicado: (2020)

Use of phage display biopanning as a tool to design CAR-T cells against glioma stem cells
por: Potez, Marine, et al.
Publicado: (2023)

Bispecific c-Met/PD-L1 CAR-T Cells Have Enhanced Therapeutic Effects on Hepatocellular Carcinoma
por: Jiang, Wei, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_jhmj6dqqkj017kt172rhs2i6cf